Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare and potentially life-threatening blood… Read More
The CASTL team is excited to announce the launch of four specialized workshops focused on Good Manufacturing Practices (GMP) in biopharmaceutical manufacturing. These workshops have been developed in direct response… Read More
Discovery of ‘ovoid cells’ reshapes our understanding of how memory works, and could open the door to new treatments for Alzheimer’s disease, epilepsy and more. Take a look around your… Read More
TORONTO, ON – Santis Health is pleased to welcome Dr. Kathie McNally as its newest Associate based out of its recently-established Atlantic Canada office. A distinguished leader in health care, Dr…. Read More
VANCOUVER, BC – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high… Read More
